Spevigo

(spesolimab)
7.5 ML spesolimab-sbzo 60 MG/ML Injection [Spevigo]
NO BLACK BOX WARNING

Dosage & administration

drug label

Spevigo prescribing information

Need to report a Spevigo issue?

ONLY FORM
Report adverse event
Learn More

prior authorization

Spevigo prior authorization resources

PDF
Complete Letter of Medical Necessity

PDF
Coverage Authorization Appeals
Learn More

Benefits investigation

PDF
BI Solution Plus Enrollment Form
Learn More

pharmacy

Spevigo preferred pharmacy

OTHER
Pharmacy List

financial assistance

Spevigo financial assistance options

Co-pay savings program

commercial only
Learn More

patient education

Spevigo patient education

Getting started on Spevigo

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

BRAND PAGE
About Spevigo
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link

BRAND PAGE
Side Effects
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Spevigo FAQs

What is the risk of using SPEVIGO during pregnancy?The limited data on the use of SPEVIGO in pregnant women are insufficient to inform a drug-associated risk of adverse pregnancy-related outcomes. However, human IgG is known to cross the placental barrier, so SPEVIGO may be transmitted from the mother to the developing fetus. In an animal reproduction study, intravenous administration of a surrogate antibody against IL36R in mice during the period of organogenesis did not elicit any reproductive toxicity.
What is the estimated background risk of birth defects and miscarriage for the indicated population?The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Is SPEVIGO safe to use during lactation?There are no data on the presence of spesolimab-sbzo in human milk, the effects on the breastfed infant, or the effects on milk production. However, spesolimab-sbzo is a monoclonal antibody and is expected to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SPEVIGO and any potential adverse effects on the breastfed infant from SPEVIGO or from the underlying maternal condition.
Is SPEVIGO safe to use in pediatric patients?The safety and effectiveness of SPEVIGO in pediatric patients have not been established.
Is there a difference in safety profile between elderly and younger patients using SPEVIGO?Clinical studies of SPEVIGO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult subjects.
FAQ Data Source

Can't find what you're looking for?

Our trained staff can help you:
Please note:
  • Access to a Field Reimbursement Manager (FRM) or Medical Science Liaison (MSL) varies by brand and may require talking with your rep first.
  • Samples are provided at the discretion of the brand.
  • We are unable to collect Protected Health Information (PHI), fill out forms, or submit them on your behalf.